RSS feed

Publications by Eva Hoff Wanderas

15 publications found

Original articles

Leon O, Guren M, Hagberg O, Glimelius B, Dahl O, Havsteen H, Naucler G, Svensson C, Tveit KM, Jakobsen A, Pfeiffer P, Wanderås E, Ekman T, Lindh B, Balteskard L, Frykholm G, Johnsson A (2014)
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines
Radiother Oncol, 113 (3), 352-8
DOI 10.1016/j.radonc.2014.10.002, PubMed 25499203

Bentzen AG, Guren MG, Vonen B, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Balteskard L (2013)
Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort
Radiother Oncol, 108 (1), 55-60
DOI 10.1016/j.radonc.2013.05.037, PubMed 23891095

Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Guren MG (2013)
Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors
Acta Oncol, 52 (4), 736-44
DOI 10.3109/0284186X.2013.770599, PubMed 23438358

Bentzen AG, Guren MG, Wanderås EH, Frykholm G, Tveit KM, Wilsgaard T, Dahl O, Balteskard L (2012)
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort
Int J Radiat Oncol Biol Phys, 83 (2), e173-80
DOI 10.1016/j.ijrobp.2011.12.062, PubMed 22436791

Sørbye H, Berglund A, Tveit KM, Ogreid D, Wanderås EH, Wentzel-Larsen T, Dahl O, Glimelius B (2007)
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer
Acta Oncol, 46 (7), 982-8
DOI 10.1080/02841860701261568, PubMed 17917829

Hølmebakk T, Wiig JN, Wanderås EH, Harbitz TB (2006)
[Protective silicone prosthesis prior to radiotherapy of recurrent colonic cancer]
Tidsskr Nor Laegeforen, 126 (4), 447-9
PubMed 16477282

Wanderås EH, Grotmol T, Fosså SD, Tretli S (1998)
Maternal health and pre- and perinatal characteristics in the etiology of testicular cancer: a prospective population- and register-based study on Norwegian males born between 1967 and 1995
Cancer Causes Control, 9 (5), 475-86
DOI 10.1023/a:1008857702380, PubMed 9934714

Wanderås EH, Fosså SD, Tretli S (1997)
Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients
Eur J Cancer, 33 (2), 244-52
DOI 10.1016/s0959-8049(96)00459-5, PubMed 9135496

Wanderås EH, Fosså SD, Tretli S (1997)
Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients
Eur J Cancer, 33 (2), 253-62
DOI 10.1016/s0959-8049(96)00458-3, PubMed 9135497

Wanderås EH, Tretli S, Fosså SD (1995)
Trends in incidence of testicular cancer in Norway 1955-1992
Eur J Cancer, 31A (12), 2044-8
DOI 10.1016/0959-8049(95)00321-5, PubMed 8562163

Wanderas E, Fossa S, Tretli S, Klepp O (1994)
Toxicity in long-term survivors after adriamycin containing chemotherapy of malignant germ-cell tumors
Int J Oncol, 4 (3), 681-8
DOI 10.3892/ijo.4.3.681, PubMed 21566977

Waehre H, Wanderaas EH, Paus E, Fosså SD (1992)
Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer
Eur Urol, 22 (1), 33-8
DOI 10.1159/000474718, PubMed 1385143

Wanderas EH, Fosså SD, Heilo A, Stenwig AE, Norman N (1990)
Serum follicle stimulating hormone--predictor of cancer in the remaining testis in patients with unilateral testicular cancer
Br J Urol, 66 (3), 315-7
DOI 10.1111/j.1464-410x.1990.tb14935.x, PubMed 2119845

Wanderås EH, Fosså SD, Tveit KM, Flokkmann A (1987)
Sequential 5-fluorouracil and methotrexate. Negative experience in metastatic colorectal cancer
Acta Oncol, 26 (4), 289-93
DOI 10.3109/02841868709089977, PubMed 3500730

Review articles

Fosså SD, Wanderås EH, Heimdal K (1994)
Second cancer after treatment of malignant germ-cell tumors
World J Urol, 12 (3), 151-4
DOI 10.1007/BF00192277, PubMed 7951342